https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-04-12 11:11:572023-04-24 14:45:30Cytovation appoints Iman Barilero as Chief Development Officer
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-02-17 09:02:112023-02-17 09:04:10Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2022-02-08 13:20:032022-02-10 14:33:23Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2022-01-26 09:49:502022-02-01 09:34:12Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2021-09-25 12:28:192021-09-25 12:28:19CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA Trial Which Now Moves to Expansion Phase
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2021-06-30 21:22:262021-06-30 21:22:26Cytovation Announces Clinical Collaboration with MSD to Evaluate its First-in-class Tumorolytic Agent CyPep-1 in Combination with KEYTRUDA
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2020-05-29 19:15:312020-05-29 19:15:31Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2019-08-08 19:12:222019-08-08 19:12:22Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors
